Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

PBLA Panbela Therapeutics

0.246
-0.008-3.15%
Close 10/06 16:00 ET
0.260
+0.014+5.88%
Post Mkt Price 10/06 19:01 ET
High
0.320
Open
0.260
Turnover
363.48K
Low
0.233
Pre Close
0.254
Volume
1.35M
Market Cap
5.11M
P/E(TTM)
Loss
52wk High
2.400
Shares
20.79M
P/E(Static)
Loss
52wk Low
0.203
Float Cap
4.11M
Bid/Ask %
92.29%
Historical High
8.800
Shs Float
16.74M
Volume Ratio
1.78
Historical Low
0.203
Dividend TTM
--
Div Yield TTM
--
P/B
-1.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
8.06%
Amplitude
34.25%
Avg Price
0.269
Lot Size
1
Float Cap
4.11M
Bid/Ask %
92.29%
Historical High
8.800
Shs Float
16.74M
Volume Ratio
1.78
Historical Low
0.203
Dividend TTM
--
P/B
-1.05
Dividend LFY
--
Turnover Ratio
8.06%
Amplitude
34.25%
Avg Price
0.269
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...